MET and neoplasm: The European Organization for Research and Treatment of Cancer (EORTC) “CREATE” trial was designed as a multi-center multi-tumor trial to evaluate crizotinib in a range of cancer types known to harbor alterations in the targets of crizotinib (ALK, MET, and ROS-1) (193).